TITLE

Drug Treatment of Obesity: Established and Emerging Therapies

AUTHOR(S)
Isidro, M. Luisa; Cordido, Fernando
PUB. DATE
June 2009
SOURCE
Mini Reviews in Medicinal Chemistry;Jun2009, Vol. 9 Issue 6, p664
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Available anti-obesity pharmacotherapy options remain very limited. The development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake, by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacological treatment options.
ACCESSION #
43974647

 

Related Articles

  • Current and novel approaches to the drug therapy of obesity. Chaput, Jean-Philippe; Tremblay, Angelo // European Journal of Clinical Pharmacology;Oct2006, Vol. 62 Issue 10, p793 

    Obesity has been described as the greatest current threat to human health. Although diet and lifestyle changes remain the cornerstones of therapy for obesity, weight losses are often small, and long-term success is disappointing. When these lifestyle-modifying attempts fail, the use of...

  • Pharmacological Treatment of Obesity: Current Standards and Future Perspectives. Romijn, J. A.; Smit, J. W. A.; Pereira, A. M.; Corssmit, E. P. M.; Pijl, H. // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Feb2006, Vol. 6 Issue 1, p119 

    The long-term effects on weight have only been studied for orlistat and sibutramine. The net effects of these drugs vary between 2-5% loss of weight after 1-2 years of treatment. However, the effects of orlistat and sibutramine on morbidity and mortality have not been studied extensively. In the...

  • Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents. Chaput, Jean-Philippe; Bérubé-Parent, Sonia; Tremblay, Angelo // Current Vascular Pharmacology;Apr2005, Vol. 3 Issue 2, p185 

    The increase in obesity prevalence is problematic as this condition is associated with health complications such as diabetes and cardiovascular diseases, more particularly when the excess body fat is stored in the deep abdominal region. The mainstay of therapy consists of behavior modification...

  • Pharmacotherapy of Childhood Obesity. Freemark, Michael // Diabetes Care;Feb2007, Vol. 30 Issue 2, p395 

    The article presents an analysis of the benefits of lifestyle intervention and pharmacotherapy to the treatment of obesity in adults and children. It cites the role of biological factors in the difficulty of losing weight. Several placebo-controlled studies performed in obese adults showed that...

  • The effects of exercise on food intake and hunger: Relationship with acylated ghrelin and leptin. Vatansever-Ozen, Serife; Tiryaki-Sonmez, Gul; Bugdayci, Guler; Ozen, Guclu // Journal of Sports Science & Medicine;Jun2011, Vol. 10 Issue 2, p283 

    This study investigated the effects of a long bout of aerobic exercise on hunger and energy intake and circulating levels of leptin and acylated ghrelin. Ten healthy male subjects undertook two, 4 h trials in a randomized crossover design. In the exercise trial subjects ran for 105 min at 50% of...

  • Alteration of hypothalamic cellular dynamics in obesity. Lee, Edward B.; Ahima, Rexford S. // Journal of Clinical Investigation;Jan2012, Vol. 122 Issue 1, p22 

    The number of people who suffer from obesity and one or more of its adverse complications is rapidly increasing. It is becoming clear that diet, exercise, and other lifestyle modifications are insufficient strategies to combat this growing problem. Greater understanding of the mechanisms...

  • Currently Available Drugs for the Treatment of Obesity: Sibutramine and Orlistat. Chaput, J.-P.; St-Pierre, S.; Tremblay, A. // Mini Reviews in Medicinal Chemistry;Jan2007, Vol. 7 Issue 1, p3 

    The currently available drugs for long-term treatment of obesity are sibutramine and orlistat. They have been shown to be able to induce significant weight loss, with important co-morbidity reduction, allowing the maintenance of reduced body weight for at least 1-2 years. Cardiostimulating and...

  • Tolerability and Safety of the New Anti-Obesity Medications. Hainer, Vojtech; Aldhoon-Hainerová, Irena // Drug Safety;Sep2014, Vol. 37 Issue 9, p693 

    Worldwide obesity prevalence has nearly doubled since 1980. Due to numerous co-morbidities, obesity represents a serious health and socioeconomic problem worldwide. Pharmacotherapy should be an integral part of comprehensive obesity management. Drug therapy can assist in weight loss and its...

  • Pharmacotherapy for obesity in menopausal women. Samat, Ashish; Rahim, Asad; Barnett, Anthony // Menopause International;Jun2008, Vol. 14 Issue 2, p57 

    Weight gain, during and after the menopause is common. Contributing factors include ethnicity, reduced physical activity, reduced lean mass, reduced resting metabolic rate and treatment with certain drugs, e.g. steroids, insulin, glitazones. Excess body weight increases the risk of medical...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics